Last Updated: September 24, 2026

Details for Patent: 8,455,494


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,455,494 protect, and when does it expire?

Patent 8,455,494 protects YUVEZZI and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,455,494
Title:Preparations and methods for ameliorating or reducing presbyopia
Abstract:This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.
Inventor(s):Herbert E. Kaufman
Assignee: Visus Therapeutics Inc
Application Number:US13/605,302
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,455,494

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Visus YUVEZZI brimonidine tartrate; carbachol SOLUTION/DROPS;OPHTHALMIC 220142-001 Jan 28, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF PRESBYOPIA ⤷  Start Trial
Visus YUVEZZI brimonidine tartrate; carbachol SOLUTION/DROPS;OPHTHALMIC 220142-001 Jan 28, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS ⤷  Start Trial
Visus YUVEZZI brimonidine tartrate; carbachol SOLUTION/DROPS;OPHTHALMIC 220142-001 Jan 28, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,455,494

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2010135731 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.